

requirements for comments are found in section 572.603 of Title 46 of the Code of Federal Regulations. Interested persons should consult this section before communicating with the Commission regarding a pending agreement.

**Agreement No.: 224-200918**

*Title:* Port of New York & New Jersey/ NSCSA (America) Inc. Container Incentive Agreement

*Parties:*

Port Authority of New York & New Jersey ("Port") NSCSA (America) Inc. ("NSCSA")

*Synopsis:* The Agreement provides for the Port to pay NSCSA an incentive of \$15.00 for each import container and \$25.00 for each export container loaded or unloaded from a vessel at the Port's marine terminals during calendar year 1995, provided each container is shipped by rail to or from points more than 260 miles from the Port.

**Agreement No.: 224-200919**

*Title:* Port of New York & New Jersey/ Solar International Shipping Agency Container Incentive Agreement

*Parties:*

Port Authority of New York & New Jersey ("Port")  
Solar International Shipping Agency ("Solar")

*Synopsis:* The Agreement provides for the Port to pay Solar an incentive of \$15.00 for each import container and \$25.00 for each export container loaded or unloaded from a vessel at the Port's marine terminals during calendar year 1995, provided each container is shipped by rail to or from points more than 260 miles from the Port.

**Agreement No.: 224-200920**

*Title:* Port of New York & New Jersey/ Orient Overseas Container Line Container Incentive Agreement

*Parties:*

Port Authority of New York & New Jersey ("Port") Orient Overseas Container Line ("OOCL")

*Synopsis:* The Agreement provides for the Port to pay OOCL an incentive of \$15.00 for each import container and \$25.00 for each export container loaded or unloaded from a vessel at the Port's marine terminals during calendar year 1995, provided each container is shipped by rail to or from points more than 260 miles from the Port.

**Agreement No.: 224-200921**

*Title:* Port of New York & New Jersey/ Hapag-Lloyd America, Inc. Container Incentive Agreement

*Parties:*

Port Authority of New York & New Jersey ("Port") Hapag-Lloyd America, Inc. ("H-L")

*Synopsis:* The Agreement provides for the Port to pay H-L an incentive of \$15.00 for each import container and \$25.00 for each export container loaded or unloaded from a vessel at the Port's marine terminals during calendar year 1995, provided each container is shipped by rail to or from points more than 260 miles from the Port.

By Order of the Federal Maritime Commission.

Dated: January 18, 1995.

**Joseph C. Polking,**

*Secretary.*

[FR Doc. 95-1672 Filed 1-23-95; 8:45 am]

BILLING CODE 6730-01-M

**Security for the Protection of the Public Indemnification of Passengers for Nonperformance of Transportation; Issuance of Certificate (Performance)**

Notice is hereby given that the following have been issued a Certificate of Financial Responsibility for Indemnification of Passengers for Nonperformance of Transportation pursuant to the provisions of Section 3, Public Law 89-777 (46 U.S.C. 817(e)) and the Federal Maritime Commission's implementing regulations at 46 CFR part 540, as amended:

Celebrity Cruises Inc. and Blue Sapphire Marine Inc., 5200 Blue Lagoon Drive, Miami, Florida 33126

Vessel: CENTURY

Dated: January 18, 1995.

**Joseph C. Polking,**

*Secretary.*

[FR Doc. 95-1696 Filed 1-23-95; 8:45 am]

BILLING CODE 6730-01-M

**FEDERAL RESERVE SYSTEM**

**Country Bank Shares Corporation; Notice of Application to Engage de novo in Permissible Nonbanking Activities**

The company listed in this notice has filed an application under § 225.23(a)(1) of the Board's Regulation Y (12 CFR 225.23(a)(1)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to commence or to engage *de novo*, either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise

noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than February 7, 1995.

**A. Federal Reserve Bank of Chicago**  
(James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690;

1. *Country Bank Shares Corporation*, Mt. Horeb, Wisconsin; to engage *de novo* in providing to others data processing and data transmission services, facilities, data bases, or access to such services, facilities, or data bases by any technological means, pursuant to § 225.25(b)(7) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, January 18, 1995.

**Jennifer J. Johnson,**

*Deputy Secretary of the Board.*

[FR Doc. 95-1700 Filed 1-23-95; 8:45 am]

BILLING CODE 6210-01-F

**L.B.S. McMullan Limited Partnership, et al.; Formations of; Acquisitions by; and Mergers of Bank Holding Companies**

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are

considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than February 17, 1995.

**A. Federal Reserve Bank of St. Louis** (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. *L.B.S. McMullan Limited Partnership*, Shelbyville, Kentucky; to become a bank holding company by acquiring 37.53 percent of the voting shares of Citizens Union Bancorp of Shelbyville, Inc., Shelbyville, Kentucky, and thereby indirectly acquire Citizens Union Bank of Shelbyville, Shelbyville, Kentucky, and First Farmers Bank and Trust Company, Owenton, Kentucky.

**B. Federal Reserve Bank of Kansas City** (John E. Yorke, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. *Vectra Banking Corporation*, Denver, Colorado; to merge with First Denver Corporation, Denver, Colorado, and thereby indirectly acquire The First National Bank of Denver, Denver, Colorado.

**C. Federal Reserve Bank of San Francisco** (Kenneth R. Binning, Director, Bank Holding Company) 101 Market Street, San Francisco, California 94105:

1. *Westamerica Bancorporation*, San Rafael, California; to acquire up to 100 percent of the voting shares of CapitolBank Sacramento, Sacramento, California.

Board of Governors of the Federal Reserve System, January 18, 1995.

**Jennifer J. Johnson,**

*Deputy Secretary of the Board.*

[FR Doc. 95-1701 Filed 1-23-95; 8:45 am]

BILLING CODE 6210-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Novel Heparin-Binding Peptides

**AGENCY:** National Institutes of Health, PHS, DHHS.

**ACTION:** Notice.

**SUMMARY:** Pursuant to the Federal Technology Transfer Act of 1986 (FTTA, 15 U.S.C. 3710; Executive Order 12591 of April 10, 1987), The National Cancer Institute (NCI) of the National Institutes of Health (NIH) of the Public Health Service (PHS) of the Department of Health and Human Services (DHHS) seeks a major pharmaceutical company which can effectively pursue the development of novel heparin-binding peptides for which a United States Patent has issued (5,357,041) and additional United States and foreign patent applications have been filed. NCI will enter into CRADA negotiations with the selected sponsor. It is the intention of NCI that the selected sponsor will be awarded a CRADA for the co-development of these peptides as inhibitors of angiogenesis and tumor growth. The CRADA would have an expected duration of three to five years.

**ADDRESSES:** Questions about this opportunity may be addressed to David R. Preston, Ph.D., Office of Technology Development, National Cancer Institute, Building 31, Room 4A51, National Institutes of Health, Bethesda, MD 20892. Phone (301) 496-0477, facsimile number (301) 402-2117. Further information may be obtained through a confidentiality agreement between the interested company and the NCI. This information will include forms necessary for examining, and applying for license to, existing relevant patents and patent applications. Under the Collaborative Research and Development Agreement (CRADA), the industrial collaborator may obtain an option to negotiate a license to government patent rights to inventions arising under the CRADA.

**DATES:** Interested parties should notify this office in writing no later than sixty (60) days from the date of this announcement in the **Federal Register**. Respondents will then be provided an additional, sixty (60) days for the filing of formal proposals.

**SUPPLEMENTARY INFORMATION:** "Cooperative Research and

Development Agreements" or "CRADA" means the anticipated joint agreement to be entered into by NCI pursuant to the Federal Technology Transfer Act of 1986 and Executive Order 12591 of October 10, 1987 to collaborate on the specific research project described below. The Division of Cancer Biology, Diagnosis and Centers (DCBDC) of NCI is seeking to develop a collaborative relationship with a major pharmaceutical company with the following aims:

- (1) Optimizing peptide and peptidomimetic activity *in vitro* and *in vivo*;
- (2) preclinical development of the synthetic peptides and mimetics; and
- (3) clinical studies as warranted.

A family of related peptides have been synthesized based on the Type I repeats of human thrombospondin that bind to heparin or related sulfated glycoconjugates with high affinity. The peptides differ from previously described heparin-binding peptides in that they do not require basic amino acid residues for binding to heparin. The peptides are potent inhibitors of interactions of heparin, heparan sulfate proteoglycans, or related sulfated glycoconjugates with adhesion molecules, growth factors, cells and some heparin-dependent enzymes. The lack of charge should be advantageous in formulating pharmaceutical agents based on these peptides for efficient delivery to their sites of action. Stable analogs of the peptides have been synthesized with increased potency and specificity. The high potency of these peptidomimetics should allow much smaller amounts of the compound to be administered and thus may reduce risks of toxicity and generation of immune responses against the compounds.

The peptides and mimetics have several defined activities: (a) Inhibition of binding of several adhesive proteins and growth factors to heparin and heparan sulfate proteoglycans; (b) inhibition of adhesive protein binding to tumor and endothelial cells; (c) promotion of tumor and endothelial cell adhesion on peptide coated substrates; and (d) modulation of tumor and endothelial cell growth and chemotaxis in response to basic fibroblast growth factor and some other growth factors *in vitro* and tumor growth *in vivo*.

Preclinical studies are in progress to characterize the activities of these peptides in modulating tumor growth, metastasis, and invasion, and in inhibiting angiogenesis. Studies will also investigate potential use of the peptides to treat other diseases associated with angiogenic responses and as inhibitors of pathogen